Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAF(V600E) melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Zhang, Gao, Frederick, Dennie T., Wu, Lawrence, Wei, Zhi, Krepler, Clemens, Srinivasan, Satish, Chae, Young Chan, Xu, Xiaowei, Choi, Harry, Dimwamwa, Elaida, Ope, Omotayo, Shannan, Batool, Basu, Devraj, Zhang, Dongmei, Guha, Manti, Xiao, Min, Randell, Sergio, Sproesser, Katrin, Xu, Wei, Liu, Jephrey, Karakousis, Giorgos C., Schuchter, Lynn M., Gangadhar, Tara C., Amaravadi, Ravi K., Gu, Mengnan, Xu, Caiyue, Ghosh, Abheek, Xu, Weiting, Tian, Tian, Zhang, Jie, Zha, Shijie, Liu, Qin, Brafford, Patricia, Weeraratna, Ashani, Davies, Michael A., Wargo, Jennifer A., Avadhani, Narayan G., Lu, Yiling, Mills, Gordon B., Altieri, Dario C., Flaherty, Keith T., Herlyn, Meenhard
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855947/
https://ncbi.nlm.nih.gov/pubmed/27043285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI82661
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items